Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Sep;39(9):1629-1634.
doi: 10.3174/ajnr.A5707. Epub 2018 Jun 28.

Prognostic Value of the Metabolic and Volumetric Parameters of 11C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis

Y-I Kim  1   2 , Y Kim  3 , J Y Lee  2 , S J Jang  4
Affiliations
Meta-Analysis

Prognostic Value of the Metabolic and Volumetric Parameters of 11C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis

Y-I Kim et al. AJNR Am J Neuroradiol. 2018 Sep.

Abstract

Background: Several studies have demonstrated that 11C-methionine positron-emission tomography provides information on prognosis.

Purpose: We performed a systematic review and meta-analysis of the prognostic value of the metabolic and volumetric parameters of 11C-methionine-PET for gliomas.

Data sources: A systematic search was performed using the following combination of keywords: "methionine," "PET," "glioma," and "prognosis."

Study selection: The inclusion criteria were the use of 11C-methionine-PET as an imaging tool, studies limited to gliomas, studies including metabolic parameters (tumor-to-normal ratio) and/or volumetric parameters (metabolic tumor volume), and studies reporting survival data. The electronic search first identified 181 records, and 14 studies were selected.

Data analysis: Event-free survival and overall survival were the outcome measures of interest. The effect of the tumor-to-normal ratio and metabolic tumor volume on survival was determined by the effect size of the hazard ratio. Hazard ratios were extracted directly from each study when provided or determined by analyzing the Kaplan-Meier curves.

Data synthesis: The combined hazard ratios of the tumor-to-normal ratio for event-free survival was 1.74 with no significance and that of the tumor-to-normal ratio for overall survival was 2.02 with significance. The combined hazard ratio of the metabolic tumor volume for event-free survival was 2.72 with significance and that of the metabolic tumor volume for overall survival was 3.50 with significance.

Limitations: The studies selected were all retrospective, and there were only 4 studies involving the metabolic tumor volume.

Conclusions: The present meta-analysis of 11C-methionine-PET suggests that the tumor-to-normal ratio for overall survival and the metabolic tumor volume for event-free survival and overall survival are significant prognostic factors for patients with gliomas.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
A flow diagram of the study.
Fig 2.
Fig 2.
Forest plot results of the EFS (A) and OS (B) based on the TNR.
Fig 3.
Fig 3.
Forest plot results of the EFS (A) and OS (B) based on the MTV.
Fig 4.
Fig 4.
Funnel plot results of the EFS based on the TNR (A), OS based on the TNR (B), EFS based on the MTV (C), and OS based on the MTV (D).
See this image and copyright information in PMC

References

    1. Rigau V, Zouaoui S, Mathieu-Daudé H, et al. ; Société Française de Neuropathologie (SFNP), Société Française de Neurochirurgie (SFNC), Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC), Association des Neuro-Oncologues d'Expression Française (ANOCEF). French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 2011;21:633–44 10.1111/j.1750-3639.2011.00491.x - DOI - PMC - PubMed
    1. Ostrom QT, Gittleman H, Liao P, et al. . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16(Suppl 4):iv1–63 10.1093/neuonc/nou223 - DOI - PMC - PubMed
    1. Behin A, Hoang-Xuan K, Carpentier AF, et al. . Primary brain tumours in adults. Lancet 2003;361:323–31 10.1016/S0140-6736(03)12328-8 - DOI - PubMed
    1. van den Bent MJ, Vogelbaum MA, Wen PY, et al. . End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009;27:2905–08 10.1200/JCO.2009.22.4998 - DOI - PMC - PubMed
    1. Hutterer M, Hattingen E, Palm C, et al. . Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol 2015;17:784–800 10.1093/neuonc/nou322 - DOI - PMC - PubMed

Publication types

LinkOut - more resources